Advertisement

Diabetic Retinopathy: Surgical Aspects

  • Xuejing Chen
  • Michelle C. LiangEmail author
Chapter

Abstract

Vision loss due to diabetic retinopathy can be devastating and results from numerous complications, including macular edema, retinal and choroidal ischemia, vitreous hemorrhage, tractional retinal detachments, epiretinal membranes (with or without vitreoretinal traction), and papillopathy [1, 2]. The Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) showed that proper blood pressure and blood glucose control can delay the progression of diabetic retinopathy [3–5]. Additionally, local therapies such as focal macular laser, panretinal photocoagulation, intravitreal anti-vascular endothelial growth factor (VEGF), and intravitreal steroids can delay progression of retinopathy and treat associated vision-threatening complications [6]. Nevertheless, some patients continue to progress and require surgical intervention with pars plana vitrectomy (PPV) for optimal vision [6]. An estimated 5% of patients with proliferative diabetic retinopathy required PPV despite laser treatment and good glycemic and hypertensive control in the Early Treatment Diabetic Retinopathy Study (ETDRS) cohort [7].

References

  1. 1.
    Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124–36.  https://doi.org/10.1016/S0140-6736(09)62124-3.CrossRefPubMedGoogle Scholar
  2. 2.
    Codenotti M, Iuliano L, Maestranzi G. Surgical management and techniques. Manag Diab Retinop. 2017;60:143–59.  https://doi.org/10.1159/000459702.CrossRefGoogle Scholar
  3. 3.
    Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the diabetes control and complications trial. Ophthalmology. 1995;102:647–61.  https://doi.org/10.1016/S0161-6420(95)30973-6.CrossRefGoogle Scholar
  4. 4.
    Group BMJP. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–13.  https://doi.org/10.1136/bmj.317.7160.703.CrossRefGoogle Scholar
  5. 5.
    Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5:431–7.  https://doi.org/10.1016/S2213-8587(17)30104-3.CrossRefPubMedGoogle Scholar
  6. 6.
    Oellers P, Mahmoud T. Surgery for proliferative diabetic retinopathy: new tips and tricks. J Ophthalmic Vis Res. 2016;11:93–7.  https://doi.org/10.4103/2008-322X.180697.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Flynn HW, Chew EY, Simons BD, et al. Pars plana vitrectomy in the early treatment diabetic retinopathy study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1992;99:1351–7.CrossRefGoogle Scholar
  8. 8.
    Akiba J, Arzabe CW, Trempe CL. Posterior vitreous detachment and neovascularization in diabetic retinopathy. Ophthalmology. 1990;97:889–91.CrossRefGoogle Scholar
  9. 9.
    Ono R, Kakehashi A, Yamagami H, et al. Prospective assessment of proliferative diabetic retinopathy with observations of posterior vitreous detachment. Int Ophthalmol. 2005;26:15–9.  https://doi.org/10.1007/s10792-005-5389-2.CrossRefPubMedGoogle Scholar
  10. 10.
    Rami El H, Barham R, Sun JK, Silva PS. Evidence-based treatment of diabetic retinopathy. Semin Ophthalmol. 2017;32:67–74.  https://doi.org/10.1080/08820538.2016.1228397.CrossRefGoogle Scholar
  11. 11.
    Helbig H, Sutter FKP. Surgical treatment of diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2004;242:704–9.  https://doi.org/10.1007/s00417-004-0977-9.CrossRefPubMedGoogle Scholar
  12. 12.
    Huang C-H, Hsieh Y-T, Yang C-M. Vitrectomy for complications of proliferative diabetic retinopathy in young adults: clinical features and surgical outcomes. Graefes Arch Clin Exp Ophthalmol. 2017;255:863–71.  https://doi.org/10.1007/s00417-016-3579-4.CrossRefPubMedGoogle Scholar
  13. 13.
    Machemer R, Buettner H, Norton EW, Parel JM. Vitrectomy: a pars plana approach. Trans Am Acad Ophthalmol Otolaryngol. 1971;75:813–20.PubMedGoogle Scholar
  14. 14.
    Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) report #1. Ophthalmology. 1985;92:492–502.Google Scholar
  15. 15.
    Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Clinical application of results of a randomized trial--diabetic retinopathy vitrectomy study report 4. The Diabetic Retinopathy Vitrectomy Study Research Group. Ophthalmology. 1988a;95:1321–34.Google Scholar
  16. 16.
    Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol. 1990;108:958–64.Google Scholar
  17. 17.
    Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial--diabetic retinopathy vitrectomy study report 3. The Diabetic Retinopathy Vitrectomy Study Research Group. Ophthalmology. 1988b;95:1307–20.Google Scholar
  18. 18.
    Gupta B, Sivaprasad S, Wong R, et al. Visual and anatomical outcomes following vitrectomy for complications of diabetic retinopathy: the DRIVE UK Study. Eye. 2012;26:510–6.  https://doi.org/10.1038/eye.2011.321.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Landers MB, Perraki AD. Management of post-vitrectomy persistent vitreous hemorrhage in pseudophakic eyes. Am J Ophthalmol. 2003;136:989–93.  https://doi.org/10.1016/S0002-9394(03)00718-9.CrossRefPubMedGoogle Scholar
  20. 20.
    Yang C-M, Su P-Y, Yeh P-T, Chen M-S. Combined rhegmatogenous and traction retinal detachment in proliferative diabetic retinopathy: clinical manifestations and surgical outcome. Can J Ophthalmol. 2008;43:192–8.  https://doi.org/10.3129/i08-007.CrossRefPubMedGoogle Scholar
  21. 21.
    Charles S, Flinn CE. The natural history of diabetic extramacular traction retinal detachment. Arch Ophthalmol. 1981;99:66–8.  https://doi.org/10.1001/archopht.1981.03930010068003.CrossRefPubMedGoogle Scholar
  22. 22.
    Yorston D, Wickham L, Benson S, et al. Predictive clinical features and outcomes of vitrectomy for proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92:365–8.  https://doi.org/10.1136/bjo.2007.124495.CrossRefPubMedGoogle Scholar
  23. 23.
    Cohen HB, McMeel JW, Franks EP. Diabetic traction detachment. Arch Ophthalmol. 1979;97:1268–72.  https://doi.org/10.1001/archopht.1979.01020020010002.CrossRefPubMedGoogle Scholar
  24. 24.
    Ramezani A, Ahmadieh H, Rozegar A, et al. Predictors and outcomes of vitrectomy and silicone oil injection in advanced diabetic retinopathy. Korean J Ophthalmol. 2017;31:217–29.  https://doi.org/10.3341/kjo.2016.0018.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Jackson TL, Nicod E, Angelis A, et al. Pars plana vitrectomy for diabetic macular edema: a systematic review, meta-analysis, and synthesis of safety literature. Retina. 2017;37:886–95.  https://doi.org/10.1097/IAE.0000000000001280.CrossRefPubMedGoogle Scholar
  26. 26.
    Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91:1464–74.CrossRefGoogle Scholar
  27. 27.
    Hikichi T, Fujio N, Akiba J, et al. Association between the short-term natural history of diabetic macular edema and the vitreomacular relationship in type II diabetes mellitus. Ophthalmology. 1997;104:473–8.  https://doi.org/10.1016/S0161-6420(97)30289-9.CrossRefPubMedGoogle Scholar
  28. 28.
    Nasrallah FP, Jalkh AE, Van Coppenolle F, et al. The role of the vitreous in diabetic macular edema. Ophthalmology. 1988;95:1335–9.CrossRefGoogle Scholar
  29. 29.
    Sivaprasad S, Ockrim Z, Massaoutis P, et al. Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina. 2008;28:1435–42.  https://doi.org/10.1097/IAE.0b013e31817f2dae.CrossRefPubMedGoogle Scholar
  30. 30.
    Jackson TL, Nicod E, Angelis A, et al. Vitreous attachment in age-related macular degeneration, diabetic macular edema, and retinal vein occlusion: a systematic review and metaanalysis. Retina. 2013;33:1099–108.  https://doi.org/10.1097/IAE.0b013e31828991d6.CrossRefPubMedGoogle Scholar
  31. 31.
    Pendergast SD, Hassan TS, Williams GA, et al. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol. 2000;130:178–86.  https://doi.org/10.1016/S0002-9394(00)00472-4.CrossRefPubMedGoogle Scholar
  32. 32.
    Simpson ARH, Dowell NG, Jackson TL, et al. Measuring the effect of pars plana vitrectomy on vitreous oxygenation using magnetic resonance imaging. Invest Ophthalmol Vis Sci. 2013;54:2028–34.  https://doi.org/10.1167/iovs.12-11258.CrossRefPubMedGoogle Scholar
  33. 33.
    Stefansson E, Landers MB, Wolbarsht ML. Increased retinal oxygen supply following pan-retinal photocoagulation and vitrectomy and lensectomy. Trans Am Ophthalmol Soc. 1981;79:307–34.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Stefansson E, Landers MB, Wolbarsht ML. Vitrectomy, lensectomy, and ocular oxygenation. Retina. 1982;2:159–66.CrossRefGoogle Scholar
  35. 35.
    Stefansson E, Novack RL, Hatchell DL. Vitrectomy prevents retinal hypoxia in branch retinal vein occlusion. Invest Ophthalmol Vis Sci. 1990;31:284–9.PubMedGoogle Scholar
  36. 36.
    Lee B, Litt M, Buchsbaum G. Rheology of the vitreous body: Part 2. Viscoelasticity of bovine and porcine vitreous. Biorheology. 2017;31:327–38.  https://doi.org/10.3233/BIR-1994-31403.CrossRefGoogle Scholar
  37. 37.
    Lee SS, Ghosn C, Yu Z, et al. Vitreous VEGF clearance is increased after vitrectomy. Invest Ophthalmol Vis Sci. 2010;51:2135–8.  https://doi.org/10.1167/iovs.09-3582.CrossRefPubMedGoogle Scholar
  38. 38.
    Stefánsson E. Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol. 2008;247:147–63.  https://doi.org/10.1007/s00417-008-0980-7.CrossRefPubMedGoogle Scholar
  39. 39.
    Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110:681–6.  https://doi.org/10.1016/S0161-6420(02)01969-3.CrossRefPubMedGoogle Scholar
  40. 40.
    Kumar A, Sinha S, Azad R, et al. Comparative evaluation of vitrectomy and dye-enhanced ILM peel with grid laser in diffuse diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2006;245:360–8.  https://doi.org/10.1007/s00417-006-0456-6.CrossRefPubMedGoogle Scholar
  41. 41.
    Patel JI, Hykin PG, Schadt M, et al. Pars plana vitrectomy with and without peeling of the inner limiting membrane for diabetic macular edema. Retina. 2006a;26:5–13.  https://doi.org/10.1097/00006982-200601000-00002.CrossRefPubMedGoogle Scholar
  42. 42.
    Patel JI, Hykin PG, Schadt M, et al. Diabetic macular oedema: pilot randomised trial of pars plana vitrectomy vs macular argon photocoagulation. Eye. 2006b;20:873–81.  https://doi.org/10.1038/sj.eye.6702012.CrossRefPubMedGoogle Scholar
  43. 43.
    Bahadir M, Ertan A, Mertoğlu O. Visual acuity comparison of vitrectomy with and without internal limiting membrane removal in the treatment of diabetic macular edema. Int Ophthalmol. 2005;26:3–8.  https://doi.org/10.1007/s10792-006-0008-4.CrossRefPubMedGoogle Scholar
  44. 44.
    Bardak Y, Cekiç O, Tiğ SU. Comparison of ICG-assisted ILM peeling and triamcinolone-assisted posterior vitreous removal in diffuse diabetic macular oedema. Eye. 2006;20:1357–9.  https://doi.org/10.1038/sj.eye.6702152.CrossRefPubMedGoogle Scholar
  45. 45.
    Doi N, Sakamoto T, Sonoda Y, et al. Comparative study of vitrectomy versus intravitreous triamcinolone for diabetic macular edema on randomized paired-eyes. Graefes Arch Clin Exp Ophthalmol. 2012;250:71–8.  https://doi.org/10.1007/s00417-011-1777-7.CrossRefPubMedGoogle Scholar
  46. 46.
    Thomas D, Bunce C, Moorman C, Laidlaw DAH. A randomised controlled feasibility trial of vitrectomy versus laser for diabetic macular oedema. Br J Ophthalmol. 2005;89:81–6.  https://doi.org/10.1136/bjo.2004.044966.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Ulrich JN. Pars plana vitrectomy with internal limiting membrane peeling for nontractional diabetic macular edema. Open Ophthalmol J. 2017;11:5–10.  https://doi.org/10.2174/1874364101711010005.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Figueroa MS, Contreras I, Noval S. Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema. Retina. 2008;28:420–6.  https://doi.org/10.1097/IAE.0b013e318159e7d2.CrossRefPubMedGoogle Scholar
  49. 49.
    Hoerauf H, Brüggemann A, Muecke M, et al. Pars plana vitrectomy for diabetic macular edema. Internal limiting membrane delamination vs posterior hyaloid removal. A prospective randomized trial. Graefes Arch Clin Exp Ophthalmol. 2011;249:997–1008.  https://doi.org/10.1007/s00417-010-1610-8.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Pollreisz A, Schmidt-Erfurth U. Diabetic cataract-pathogenesis, epidemiology and treatment. J Ophthalmol. 2010;2010:608751–8.  https://doi.org/10.1155/2010/608751.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Berrocal MH, Acaba LA, Acaba A. Surgery for diabetic eye complications. Curr Diab Rep. 2016;16:99.  https://doi.org/10.1007/s11892-016-0787-6.CrossRefPubMedGoogle Scholar
  52. 52.
    Banerjee PJ, Moya R, Bunce C, et al. Long-term survival rates of patients undergoing vitrectomy for proliferative diabetic retinopathy. Ophthalmic Epidemiol. 2016;23:94–8.  https://doi.org/10.3109/09286586.2015.1089578.CrossRefPubMedGoogle Scholar
  53. 53.
    Gollamudi SR, Smiddy WE, Schachat AP, et al. Long-term survival rate after vitreous surgery for complications of diabetic retinopathy. Ophthalmology. 1991;98:18–22.CrossRefGoogle Scholar
  54. 54.
    Helbig H, Kellner U, Bornfeld N, Foerster MH. Life expectancy of diabetic patients undergoing vitreous surgery. Br J Ophthalmol. 1996;80:640–3.CrossRefGoogle Scholar
  55. 55.
    Lux A, Ostri C, Dyrberg E, et al. Survival rates after diabetic vitrectomy compared with standard diabetes and general populations. Acta Ophthalmol (Oxf). 2012;90:e650–2.  https://doi.org/10.1111/j.1755-3768.2012.02404.x.CrossRefGoogle Scholar
  56. 56.
    Summanen P, Karhunen U, Laatikainen L. Characteristics and survival of diabetic patients undergoing vitreous surgery. Acta Ophthalmol (Oxf). 1987;65:197–202.CrossRefGoogle Scholar
  57. 57.
    Uchio E, Inamura M, Ohno S, et al. Survival rate after vitreous surgery in patients with diabetic retinopathy. Ophthalmologica. 1993;206:83–8.CrossRefGoogle Scholar
  58. 58.
    Shah VA, Brown JS, Mahmoud TH. Correlation of outer retinal microstucture and foveal thickness with visual acuity after pars plana vitrectomy for complications of proliferative diabetic retinopathy. Retina. 2012;32:1775–80.  https://doi.org/10.1097/IAE.0b013e318255068a.CrossRefPubMedGoogle Scholar
  59. 59.
    Arevalo JF, Maia M, Flynn HW, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92:213–6.  https://doi.org/10.1136/bjo.2007.127142.CrossRefPubMedGoogle Scholar
  60. 60.
    Arevalo JF, Wu L, Sanchez JG, et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye. 2009;23:117–23.  https://doi.org/10.1038/sj.eye.6702980.CrossRefPubMedGoogle Scholar
  61. 61.
    Mitamura Y, Ogata K, Oshitari T, et al. Retinal detachment with macular hole following intravitreal bevacizumab in patient with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92:717–8.  https://doi.org/10.1136/bjo.2008.139378.CrossRefPubMedGoogle Scholar
  62. 62.
    Moradian S, Ahmadieh H, Malihi M, et al. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2008;246:1699–705.  https://doi.org/10.1007/s00417-008-0914-4.CrossRefPubMedGoogle Scholar
  63. 63.
    Oshima Y, Shima C, Wakabayashi T, et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology. 2009;116:927–38.  https://doi.org/10.1016/j.ophtha.2008.11.005.CrossRefPubMedGoogle Scholar
  64. 64.
    Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy. JAMA. 2015;314:2137–46.  https://doi.org/10.1001/jama.2015.15217.CrossRefGoogle Scholar
  65. 65.
    Sharma T, Fong A, Lai TY, et al. Surgical treatment for diabetic vitreoretinal diseases: a review. Clin Experiment Ophthalmol. 2016;44:340–54.  https://doi.org/10.1111/ceo.12752.CrossRefPubMedGoogle Scholar
  66. 66.
    Jackson TL, Johnston RL, Donachie PHJ, et al. The Royal College of Ophthalmologists’ National ophthalmology database study of vitreoretinal surgery: report 6, diabetic vitrectomy. JAMA Ophthalmol. 2016;134:79–85. quiz 120.  https://doi.org/10.1001/jamaophthalmol.2015.4587.CrossRefPubMedGoogle Scholar
  67. 67.
    Sima P, Zoran T. Long-term results of vitreous surgery for proliferative diabetic retinopathy. Doc Ophthalmol. 1994;87:223–32.CrossRefGoogle Scholar
  68. 68.
    Douglas MJ, Scott IU, Flynn HW. Pars plana lensectomy, pars plana vitrectomy, and silicone oil tamponade as initial management of cataract and combined traction/rhegmatogenous retinal detachment involving the macula associated with severe proliferative diabetic retinopathy. Ophthalmic Surg Lasers Imaging. 2003;34:270–8.PubMedGoogle Scholar
  69. 69.
    Balakrishnan D, Jain B, Nayaka A, et al. Role of tamponade in vitrectomy for proliferative diabetic retinopathy with vitreous hemorrhage. Semin Ophthalmol. 2017;32:488–91.  https://doi.org/10.3109/08820538.2015.1120757.CrossRefPubMedGoogle Scholar
  70. 70.
    Yang C-M, Yeh P-T, Yang C-H. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology. 2007;114:710–5.  https://doi.org/10.1016/j.ophtha.2006.07.047.CrossRefPubMedGoogle Scholar
  71. 71.
    Hubschman J-P, Gupta A, Bourla DH, et al. 20-, 23-, and 25-gauge vitreous cutters: performance and characteristics evaluation. Retina. 2008;28:249–57.  https://doi.org/10.1097/IAE.0b013e31815ec2b3.CrossRefPubMedGoogle Scholar
  72. 72.
    Mikhail M, Ali-Ridha A, Chorfi S, Kapusta MA. Long-term outcomes of sutureless 25-G+ pars-plana vitrectomy for the management of diabetic tractional retinal detachment. Graefes Arch Clin Exp Ophthalmol. 2017;255:255–61.  https://doi.org/10.1007/s00417-016-3442-7.CrossRefPubMedGoogle Scholar
  73. 73.
    Berrocal MH. All-probe vitrectomy dissection techniques for diabetic tractional retinal detachments: lift and shave. Retina. 2017;38:s2.  https://doi.org/10.1097/IAE.0000000000001884.CrossRefGoogle Scholar
  74. 74.
    Falkner-Radler CI, Glittenberg C, Gabriel M, Binder S. Intrasurgical microscope-integrated spectral domain optical coherence tomography-assisted membrane peeling. Retina. 2015;35:2100–6.  https://doi.org/10.1097/IAE.0000000000000596.CrossRefPubMedGoogle Scholar
  75. 75.
    Charles S. Diabetic retinopathy vitrectomy study. Arch Ophthalmol. 1986;104:486–8.CrossRefGoogle Scholar
  76. 76.
    Kamura Y, Sato Y, Deguchi Y, Yagi F. Iatrogenic retinal breaks during 20-gauge vitrectomy for proliferative diabetic retinopathy. Clin Ophthalmol. 2012;7:29.  https://doi.org/10.2147/OPTH.S38784.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Kharrat W, Turki K, Ben Amor H, et al. Use of silicone oil in vitreal hemorrhage complicating proliferated diabetic retinopathy. J Fr Ophtalmol. 2009;32:98–103.  https://doi.org/10.1016/j.jfo.2009.01.002.CrossRefPubMedGoogle Scholar
  78. 78.
    Gupta V. Surgical management of diabetic retinopathy. Middle East Afr J Ophthalmol. 2013;20:283.  https://doi.org/10.4103/0974-9233.120003.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Chen W-L, Lin C-T, Ko P-S, et al. In vivo confocal microscopic findings of corneal wound healing after corneal epithelial debridement in diabetic vitrectomy. Ophthalmology. 2009;116:1038–47.  https://doi.org/10.1016/j.ophtha.2009.01.002.CrossRefPubMedGoogle Scholar
  80. 80.
    Chen H-F, Yeung L, Yang K-J, Sun C-C. Persistent corneal epithelial defect after pars plana vitrectomy. Retina. 2016;36:148–55.  https://doi.org/10.1097/IAE.0000000000000657.CrossRefPubMedGoogle Scholar
  81. 81.
    Haimann MH, Abrams GW. Prevention of lens opacification during diabetic vitrectomy. Ophthalmology. 1984;91:116–21.CrossRefGoogle Scholar
  82. 82.
    Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology. 2009;116:1943–8.  https://doi.org/10.1016/j.ophtha.2009.07.001.CrossRefPubMedGoogle Scholar
  83. 83.
    Khuthaila MK, Hsu J, Chiang A, et al. Postoperative vitreous hemorrhage after diabetic 23-gauge pars plana vitrectomy. Am J Ophthalmol. 2013;155:757–63– 763.e1–2.  https://doi.org/10.1016/j.ajo.2012.11.004.CrossRefPubMedGoogle Scholar
  84. 84.
    Lee BJ, Yu HG. Vitreous hemorrhage after the 25-gauge transconjunctival sutureless vitrectomy for proliferative diabetic retinopathy. Retina. 2010;30:1671–7.  https://doi.org/10.1097/IAE.0b013e3181dcfb79.CrossRefPubMedGoogle Scholar
  85. 85.
    Lo WR, Kim SJ, Aaberg TM, et al. Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin). Retina. 2009;29:926–31.  https://doi.org/10.1097/IAE.0b013e3181a8eb88.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Sato T, Morita S-I, Bando H, et al. Early vitreous hemorrhage after vitrectomy with preoperative intravitreal bevacizumab for proliferative diabetic retinopathy. Middle East Afr J Ophthalmol. 2013;20:51–5.  https://doi.org/10.4103/0974-9233.106387.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Sato T, Tsuboi K, Nakashima H, Emi K. Characteristics of cases with postoperative vitreous hemorrhage after 25-gauge vitrectomy for repair of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255:665–71.  https://doi.org/10.1007/s00417-016-3522-8.CrossRefPubMedGoogle Scholar
  88. 88.
    Bhende M, Agraharam SG, Gopal L, et al. Ultrasound biomicroscopy of sclerotomy sites after pars plana vitrectomy for diabetic vitreous hemorrhage. Ophthalmology. 2000;107:1729–36.CrossRefGoogle Scholar
  89. 89.
    Hershberger VS, Augsburger JJ, HUTCHINS RK, et al. Fibrovascular ingrowth at sclerotomy sites in vitrectomized diabetic eyes with recurrent vitreous hemorrhage: ultrasound biomicroscopy findings. Ophthalmology. 2004;111:1215–21.  https://doi.org/10.1016/j.ophtha.2003.08.043.CrossRefPubMedGoogle Scholar
  90. 90.
    Krieger AE. The pars plana incision: experimental studies, pathologic observations, and clinical experience. Trans Am Ophthalmol Soc. 1991;89:549–621.PubMedPubMedCentralGoogle Scholar
  91. 91.
    Rezende FA, Qian CX, Robert M-C. Fibrovascular ingrowth after 25-gauge transconjunctival vitrectomy in proliferative diabetic retinopathy. Ophthal Surg Lasers Imag Retina. 2013;44:405–8.  https://doi.org/10.3928/23258160-20130604-03.CrossRefGoogle Scholar
  92. 92.
    Hsu Y-J, Hsieh Y-T, Yeh P-T, et al. Combined tractional and rhegmatogenous retinal detachment in proliferative diabetic retinopathy in the anti-VEGF era. J Ophthalmol. 2014;2014:917375–11.  https://doi.org/10.1155/2014/917375.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Schrey S, Krepler K, Wedrich A. Incidence of rhegmatogenous retinal detachment after vitrectomy in eyes of diabetic patients. Retina. 2006;26:149–52.CrossRefGoogle Scholar
  94. 94.
    Hiraoka M, Amano S, Oshika T, et al. Factors contributing to corneal complications after vitrectomy in diabetic patients. Jpn J Ophthalmol. 2001;45:492–5.CrossRefGoogle Scholar
  95. 95.
    Chiang W-Y, Lee J-J, Kuo H-K, et al. Factors associated with corneal epithelial defects after pars plana vitrectomy. Int Ophthalmol. 2017;116:1038–6.  https://doi.org/10.1007/s10792-016-0429-7.CrossRefGoogle Scholar
  96. 96.
    Larsson LI, Bourne WM, Pach JM, Brubaker RF. Structure and function of the corneal endothelium in diabetes mellitus type I and type II. Arch Ophthalmol. 1996;114:9–14.CrossRefGoogle Scholar
  97. 97.
    Módis L, Szalai E, Kertész K, et al. Evaluation of the corneal endothelium in patients with diabetes mellitus type I and II. Histol Histopathol. 2010;25:1531–7.  https://doi.org/10.14670/HH-25.1531.CrossRefPubMedGoogle Scholar
  98. 98.
    Roszkowska AM, Tringali CG, Colosi P, et al. Corneal endothelium evaluation in type I and type II diabetes mellitus. Ophthalmologica. 1999;213:258–61.CrossRefGoogle Scholar
  99. 99.
    Hashimoto R, Sugiyama T, Masahara H, et al. Impaired autoregulation of blood flow at the optic nerve head during vitrectomy in patients with type 2 diabetes. Am J Ophthalmol. 2017;181:125–33.  https://doi.org/10.1016/j.ajo.2017.06.021.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Boston Medical CenterBoston University Eye AssociatesBostonUSA
  2. 2.New England Eye CenterTufts Medical CenterBostonUSA
  3. 3.Retina DivisionOphthalmic Consultants of BostonBostonUSA

Personalised recommendations